Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0) announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, strengthening its executive leadership as the company prepares for a planned U.S. securities exchange listing and advances L-DOS47 into a Phase IB/Randomized Phase II study for first-line non-small cell lung cancer (NSCLC).
“The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix’s growth.”
With the preparation of a base shelf prospectus underway and auditor review of second-quarter financials completed, the company is executing on a clear capital markets roadmap. “Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution. Together, they significantly strengthen our ability to deliver on our clinical, corporate and capital markets objectives,” Mehrling added.
Helen Middleton, BPharm, LPC, brings more than 30 years of experience across pharmacy, law, and the global life sciences industry. A qualified life sciences lawyer and registered clinical pharmacist, she has advised pharmaceutical, biotechnology, and medical technology companies across the product life cycle. Her career includes senior legal roles with Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. As General Counsel, she will oversee Helix’s legal affairs, governance, compliance, and strategic transactions, supporting the company’s clinical advancement and planned U.S. listing.
David Browning, MBA, brings more than 30 years of experience leading global clinical development programs across biotechnology, pharmaceutical, contract research organization, and academic sectors. He has overseen more than 30 Phase I-III clinical studies spanning first-in-human studies through regulatory approval, and has built and led global oncology clinical operations teams across North America, Europe, Latin America, South Africa, and the Asia-Pacific region. As Vice President of Clinical Operations, he will lead operational planning and execution of Helix’s clinical programs, including LDOS007, while expanding capabilities for future pipeline growth.
Helix BioPharma is an oncology company focused on bringing near-term solutions for hard-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances pre-IND candidates LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug. For more information, visit https://www.helixbiopharma.com/.
